je.st
news
Tag: or
QUIZ: Are You a Siri, a Cortana, or a Google Now?
2014-05-14 22:36:37| PC Magazine Cell Phones Product Guide
Three major smartphone platforms, three digital assistant services, three different virtual personalities. Find out which one matches yours in our quiz.
Heartland Express Inc Files (8-K) Disclosing Change in Directors or Principal Officers
2014-05-14 18:33:44| Trucking - Topix.net
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Item 5.02 Effective May 8, 2014, Richard L. Meehan transitioned out of his role as Heartland Express, Inc.'s Executive Vice President of Marketing and Operations but still remains an employee of ... (more)
Tags: or
change
files
principal
Rocky Brands, Inc. Files (8-K) Disclosing Change in Directors or...
2014-05-13 17:31:07| Footwear - Topix.net
ROCKY BRANDS, INC. FILES Disclosing Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Does Apple Need a Large-Screen Smartphone or Phablet?
2014-05-12 22:35:00| PC Magazine Notebooks Product Guide
It is time for Apple to look to a future where more choices in screen sizes drive its smartphone plans.
Tags: or
apple
smartphone
largescreen
FDA Approves ZONTIVITY (vorapaxar), First-in-Class PAR-1 Antagonist, for the Reduction of Thrombotic Cardiovascular Events in Patients with a History of Heart Attack or with Peripheral Arterial Disease
2014-05-12 13:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. ZONTIVITY Added to Standard of Care Demonstrated Long-Term Benefit Through Three Years WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ZONTIVITY (vorapaxar) for the reduction of thrombotic cardiovascular events in patients with a history of heart attack (myocardial infarction) or in patients with narrowing of leg arteries, called peripheral arterial disease (PAD). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orPatrick Witmer, 267-305-4910orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] next »